Introduction

Before the Coronavirus Disease 2019 (COVID-19) arrival and its pandemic, dengue was already a significant cause of epidemics in South East Asia and Latin America. In 2020 with their cocirculation, coinfections began to be observed and reported in different countries. As expected, this syndemic is evident in different areas and deserves proper characterisation and studies in Peru.

Methods

We retrospectively assessed the clinical, epidemiological, diagnostic characteristics and outcomes in a Social Security Hospital of Chiclayo, Lambayeque, Peru, of patients that were diagnosed simultaneously with COVID-19 and dengue during May–August 2020.

Results

A total of 50 patients with COVID-19/dengue coinfection were identified. Of them, 60% presented thrombocytopenia, and 52% fever, among other findings. The case fatality rate in this group was 28%, being higher in those patients initially classified as severe dengue (100%), as well as in females (55%) than males (21%) (OR = 4.65; 95%CI 1.18–18.45).

Discussion

Co-occurrence of COVID-19/Dengue is growing as a consequence of the syndemic of these viral diseases in endemic areas, such as Latin America, and as both conditions may evolve to severe disease, their epidemiological but clinical interaction in terms of outcomes need further assessment in future studies in the region.

中文翻译：

---

2020 年 5 月至 8 月秘鲁兰巴耶克严重急性呼吸系统综合症冠状病毒 2 和登革热病毒合并感染患者的特征：回顾性分析

介绍

在 2019 年冠状病毒病 (COVID-19) 到来并大流行之前，登革热已经是东南亚和拉丁美洲流行的重要原因。2020 年，随着它们的共同传播，不同国家开始观察到并报告合并感染。正如预期的那样，这种综合症在不同地区都很明显，值得在秘鲁进行适当的描述和研究。

方法

我们回顾性评估了 2020 年 5 月至 8 月期间在秘鲁兰巴耶克奇克拉约社会保障医院被同时诊断为 COVID-19 和登革热的患者的临床、流行病学、诊断特征和结果。

结果

共确定了 50 名 COVID-19/登革热合并感染患者。其中，60% 出现血小板减少症，52% 出现发热等症状。该组的病死率为 28%，最初归类为重症登革热的患者 (100%) 以及女性 (55%) 高于男性 (21%)（OR = 4.65；95%CI 1.18 –18.45）。

讨论

由于这些病毒性疾病在流行地区（例如拉丁美洲）的综合流行，COVID-19/登革热的同时发生正在增加，并且由于这两种情况都可能演变成严重疾病，因此它们在结果方面的流行病学和临床相互作用需要在该地区未来的研究中进一步评估。